• NuWays reiterated a BUY on Eckert & Ziegler, cut its 12-month target price to EUR 21.5 from EUR 23.
• Report flagged rising competition in Ga-68 generators as Curium prepares an H2 2026 rollout of its EU-approved GalenVita product.
• NuWays still forecast Ga-68 sales growth near 10% CAGR to about EUR 100 million by 2030, despite an expected market-share decline.
• Q2 sales seen down 4% year on year to EUR 77 million; adjusted EBIT projected down 3% to EUR 17.9 million.
• Valuation cited at about 8x 2026 EV/EBITDA, below a three-year average near 12.5x.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News (Ref. ID: rc_26272) on July 23, 2026, and is solely responsible for the information contained therein.